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Abstract The objective of this study was to compare the
stability, survival, and tolerability of 2 percutaneous
osseointegrated titanium implants for bone conduction
hearing: a 4.5-mm diameter implant (test) and a 3.75-mm
diameter implant (control). Fifty-seven adult patients were
included in this randomized controlled clinical trial. Sixty
implants were allocated in a 2:1 (test–control) ratio. Fol-
low-up visits were scheduled at 7, 14, 21, and 28 days; 6
and 12 weeks; and 6 months. At every visit, implant sta-
bility quotient (ISQ) values were recorded by means of
resonance frequency analysis (RFA) and skin reactions
were evaluated according to the Holgers classification.
Implants were loaded with the bone conduction device at
3 weeks. Hearing-related quality of life was evaluated us-
ing the Abbreviated Profile of Hearing Aid Benefit
(APHAB), the Glasgow Benefit Inventory (GBI), and the
Glasgow Health Status Inventory (GHSI). ISQ values were
statistically significantly higher for the test implant com-
pared to the control implant. No implants were lost and soft
tissue reactions were comparable for both implants. Posi-
tive results were reported in the hearing-related quality of
life questionnaires. These 6-month results indicate that
both implants and their corresponding hearing devices are
safe options for hearing rehabilitation in patients with the
appropriate indications. Loading at 3 weeks did not affect
the stability of either implant.
Keywords Bone-anchored hearing aid  Bone-anchored
hearing system  Baha  Ponto  Bone conduction  Implant
stability quotient (ISQ)  Resonance frequency analysis
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Introduction
Percutaneous osseointegrated titanium implants have been
used to attach vibrating bone conduction devices to the
temporal bone since 1977 [1]. Both implants and devices,
as well as the indications for application, have been studied
extensively [2, 3]. The clinical outcomes of these implants
have been reported in large populations: long-term implant
survival rates vary between 81.5 and 98.4 %, while com-
plications generally involve soft tissue inflammation [4–6].
Severe complications are rare [4, 5].
Recently, the designs of these bone-anchored hearing
implants have evolved to include wider diameters, based on
the known advantages of wider implants in dentistry [7].
These 4.5-mm-wide implants provide a larger contact
surface between the implant and the bone compared to the
3.75-mm-wide implants of the previous generation, which
results in higher reported implant stability quotients (ISQ)
and high implant survival rates [8, 9]. Moreover, wider
implants appear to have higher levels of initial stability,
which allows for early loading of the implant with the
device. Loading wider implants has been reported to be
safe at 3 weeks after surgery [10].
The current randomized controlled clinical trial inves-
tigated ISQ, implant survival, and soft tissue tolerability of
a new wide implant in comparison to a previous generation
implant in the first 6 months after implantation. Early
loading of both implants was studied, with all implants
loaded at 3 weeks. Subjective benefits of the bone
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The test implant was the wide Ponto implant (diameter
4.5 mm, length 4 mm) and the control implant was the
previous generation Ponto implant (diameter 3.75 mm,
length 4 mm). Both implants used the same 6-mm abut-
ment. The implants and abutments are developed and
manufactured by Oticon Medical AB (Askim, Sweden) and
are displayed in Fig. 1.
Out of all of the patients indicated for a percutaneous
bone conduction device in our center, 57 adult patients with
a total of 60 implants were consecutively included. Eligi-
bility criteria were as follows: indication for a percutaneous
implant; age of 18 years or older; bone thickness of at least
4 mm at the implant site; written informed consent given;
abutment of 6 mm required (not longer); ability to par-
ticipate in follow-up visits; no history of psychiatric dis-
eases; no mental disabilities; no presumed doubt, for any
reason, that the patient would not be able to attend all fol-
low-up visits; no presence of diseases or use of treatments
known to compromise bone quality at the implant site (e.g.,
radiotherapy, osteoporosis, diabetes mellitus).
Study design
The current study was designed as an open randomized
controlled clinical trial in our tertiary referral center. The
primary outcome parameter was implant stability measured
as ISQ low values in the first 6 months after implantation.
Secondary objectives were to compare ISQ high values in the
same period, ISQ low and high values at all visits, time to
stability dip (in ISQ low) if applicable, implant survival, soft
tissue reactions during all visits, and quality of life outcomes.
The sample size was based on the primary efficacy
variable. A weighted average of ISQ low values during the
6-month follow-up period was obtained by the mean area
under the curve (AUC) calculation using the trapezoid rule
with all ISQ low measurements over the first 6 months. Data
from a similarly designed previous study [11] were used for
the sample size calculation. An expected difference of 4.5 in
the mean AUC of the ISQ low values of the test and the
control groups, with unequal standard deviations of 2.8 and
5.5, respectively, were used for determining the sample size.
A 2-sided t test with Satterthwaite’s correction for unequal
variances was performed. For a power of 90 %, significance
level of 0.05, and randomization ratio of 2:1, a total of 60
implants needed to be included.
Randomization was performed in a 2:1 ratio (test–con-
trol). A computer-generated list of random allocations was
used. The group assignments were enclosed in sequentially
numbered opaque sealed envelopes. The randomization was
blinded to the patients and investigators until the surgery
was performed. Patients were allocated in consecutive order.
Blinding of the investigators after the group assignments
were made was not feasible because the appearances of the
implants and instruments used during surgery were clearly
different. Because most patients were operated under local
anesthesia, the patients were also not blinded.
Implants and abutments were placed in a single-stage
surgical procedure. The linear incision technique with
subcutaneous tissue reduction was applied in all cases [12].
Implants were alternately placed within or posterior to the
incision line. In accordance with the study protocol, fol-
low-up visits were scheduled at 7, 14, 21, and 28 days; 6
and 12 weeks; and 6 months. At each visit, resonance
frequency analysis (RFA) was used to establish the implant
stability quotient (ISQ). RFA uses magnetic pulses gener-
ated by the Osstell ISQ device (Osstell AB, Go¨teborg,
Sweden) to excite the SmartPeg (type 55) that is connected
to the abutment, which leads to vibration of the implant–
abutment system. The intensity of these vibrations is ana-
lyzed by the device that computes the ISQ, which is an
indication of the rigidity of the implant–bone interface
[13]. Perpendicular measurements result in an ISQ high
value and an ISQ low value. At each visit, the skin status
was also assessed according to the Holgers classification
[14]. Three weeks after surgery, the patients were fitted
with the bone conduction device. The benefit of the bone
conduction system was assessed using 3 questionnaires: the
Abbreviated Profile of Hearing Aid Benefit (APHAB) [15],
the Glasgow Benefit Inventory (GBI), and the Glasgow
Health Status Inventory (GHSI) [16]. APHAB and GHSI
outcomes were only included in the analysis when both the
baseline screening before implantation and the 6-monthFig. 1 Control (a) and test (b) implants with abutments
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evaluation had been completed. In cases where patients
used hearing aids at the baseline evaluation, they were
asked to complete the baseline questionnaire both for the
aided and unaided conditions. The unaided condition was
used as the baseline measurement for analyzing the benefit
of the bone conduction system at 6 months.
Statistical analysis
Data management and statistical analyses were performed
by external data managers and biostatisticians (Statistiska
Konsultgruppen, Go¨teborg, Sweden) according to a pre-
defined statistical analysis plan.
For comparisons between the test and control groups,
Mann–Whitney U tests were used for all continuous vari-
ables, Mantel–Haenszel Chi-square tests were used for all
ordered categorical variables, Fisher’s exact test was used
for all dichotomous variables, and Chi-square tests were
used for all non-ordered categorical variables. For changes
over time, Wilcoxon signed rank tests (continuous vari-
ables) and sign tests (order categorical variables, dichoto-
mous variables) were used. Groups were compared
according to the intention-to-treat principle. For subjects
lost to follow-up, last observation carried forward was used
for ISQ measurements in the AUC calculations.
For implant variables, bilaterally implanted patients who
received both a control and a test implant were included in
both analyses. Patients who received 2 test or 2 control
implants were represented by the mean of the 2 measure-
ments for continuous variables or the worst value for
categorical variables. For patient variables, bilaterally im-
planted patients who received both control and test im-
plants were included in descriptive statistics but excluded
in formal analyses on the patient level.
All tests were 2 tailed with significance levels of 0.05
and were executed using SAS v9.2 and v9.3 software (SAS
Institute Inc., Cary, NC, USA).
Ethical considerations
This clinical investigation was performed in accordance
with the current version of the Declaration of Helsinki
(Washington 2002, ISO 14155), Good Clinical Practice
(International Conference on Harmonization Good Clinical
Practice) and was approved by the local ethical committee.
Results
Patients
Fifty-seven patients with a total of 60 bone-anchored hearing
implants were included in the randomization, with 39
implants in the test group and 21 in the control group.
Surgeries were performed between June 2012 and January
2014. Baseline demographic information is shown in
Table 1. No significant differences were found between the
test and control populations. Three patients received bilateral
implants; 2 of these patients were randomized for both a test
and a control implant, and 1 patient received 2 test implants.
All randomized patients received their allocated treatment
and could be included in the final 6-month analysis.
Implant stability quotient
The mean AUC for ISQ low was 64.4 (SD 3.0; range
55.5–70.1) for test implants (n = 38) and 59.5 (SD 2.2;
range 55.5–63.5) for control implants (n = 21). The dif-
ference between these groups of 4.9 ISQ points (95 % CI
3.4–6.4; p\ 0.0001) was statistically significant. For ISQ
high, a difference of 3.2 (95 % CI 1.7–4.7; p\ 0.0001)
was observed during the 6-month follow-up, with a mean
AUC of 65.8 (SD 2.7; range 57.0–70.5) for the test implant
and 62.6 (SD 2.8; range 56.9–66.8) for the control implant.
At all follow-up visits, statistically significant differences
in mean ISQs between both groups were recorded. The
results are displayed in Fig. 2. The mean increase in ISQ
from baseline is statistically significant in both groups;
however, the increase in ISQ from baseline for the test
implant is statistically significantly stronger compared to
the increase for the control implant. The ISQ dip at 42 days
for the test implant can be ascribed to a single implant that
displayed a very low ISQ (ISQ low 46, ISQ high 52) but
remained clinically stable and presented with an ISQ
within the normal range at the next follow-up appointment.
No dip in mean ISQ was observed, as the ISQ high and
ISQ low values were higher than the baseline ISQ values
(at surgery) at all follow-up visits.
Implants were loaded 3 weeks after surgery (with a
2-day range) in all but 1 patient (loaded at 24 days). This
early loading moment did not seem to influence ISQ val-
ues, as these progressed positively in both implants.
At 6 months, a mean increase in the ISQ low from the
time of surgery of 4.5 (SD 4.6; range -4 to 29) was ob-
served for the total group (n = 59), which was significantly
different from the ISQ low at the time of surgery
(p\ 0.0001). The mean increase was 5.2 (SD 5.0; range
-4 to 29) in the test group and 3.2 (SD 3.7; range -3 to 13)
in the control group. The mean difference in the increase in
ISQ low between both groups was statistically significant
(95 % CI -0.5 to 4.5; p = 0.03).
Survival and tolerability
No implants were lost during the follow-up period. In
each experimental group, 1 implant required surgical
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revision of the soft tissue; 1 patient who suffered from
psoriasis presented with insufficient skin healing after
surgery and the other patient presented with skin par-
tially overgrowing the abutment. Three implants (7.9 %)
in the test group and 2 implants (9.5 %) in the control
group developed adverse skin reactions (Holgers grade
2–4). Results related to soft tissue reactions are
displayed in Fig. 3. The analysis of soft tissue statuses
throughout the follow-up period revealed findings of
Holgers grade 0 in 86.8 % (test) and 89.0 % (control) of
visits, Holgers grade 1 in 12.1 % (test) and 9.1 %
(control) of visits, Holgers grade 2 in 1.1 % (test) and
1.3 % (control) of visits, Holgers grade 3 in 0.0 % (test)
and 0.6 % (control) of visits, and no Holgers grade 4
cases over all of the visits. Two out of the 5 patients
who presented with adverse skin reactions suffered from
skin diseases. Furthermore, no statistically significant
differences were noted in other postoperative compli-
cations: bleeding or hematoma [1 test (2.6 %) vs 1
control (4.8 %) implant], pain or numbness [4 test
(10.5 %) vs 2 control (9.5 %) implants], and wound
dehiscence [2 test 5.3 % vs 3 control (14.3 %) im-
plants]. Additionally, skin height did not differ between
the groups.
Table 1 Patient demographics
and baseline characteristics
Variables Test (n = 38) Control (n = 21) p value
Gender, n (%)
Male 15 (39.5) 9 (42.9) 1.0000
Female 23 (60.5) 12 (57.1)
Age in years, mean (SD) 53.7 (12.2) 53.0 (16.0) 0.5469
Smoking at baseline, n (%) 6 (15.8) 6 (28.6) 0.3511
Body mass index, mean (SD) 25.9 (4.2) 25.4 (4.0) 0.7635
Skin disease, n (%) 4 (10.5) 3 (14.3) 0.9176
Indication for bone-anchored hearing implant, n (%)
Acquired conductive/mixed hearing loss 25 (65.8) 17 (81.0) 0.5279
Congenital conductive hearing loss 1 (2.6) 1 (4.8) 1.0000
Single-sided deafness 13 (34.2) 3 (14.3) 0.2018
Fig. 2 Box-and-whisker plots of ISQ low and ISQ high measure-
ments. The mean (cross) and median (horizontal line) are defined
within each box plot. Dots represent outlier values
Fig. 3 Soft tissue tolerability for test and control groups as a
percentage of all visits according to the Holgers classification. Note
that only Holgers grade 0–3 are depicted, as no Holgers grade 4 was
observed
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Quality of life
The GBI questionnaire was completed 12 weeks after
surgery. Eight patients completed the questionnaire outside
of the defined visit window (mean of 22 days after the
planned visit date). These results were still included in the
final analysis. No differences were observed in the out-
comes between the test and control groups. The results are
shown in Table 2.
All patients completed the APHAB and GHSI ques-
tionnaires 6 months after surgery. However, 5 patients did
not complete baseline questionnaires and were conse-
quently excluded from the benefit analysis. One additional
patient did not complete the baseline APHAB, while an-
other 3 patients were excluded from the benefit analysis
using the GHSI because of incomplete data on the 6-month
questionnaire. The outcomes of these questionnaires are
displayed in Fig. 4. For the GHSI, significant improvement
was observed for the total and general scores, but not for
the social and physical subscales. The APHAB indicated
that there was statistically significant improvement on all
of the subscales in the aided condition compared to the
unaided condition.
Discussion
The current randomized controlled clinical trial compared
outcomes at 6 months of 2 percutaneous bone-anchored
hearing implants for bone conduction devices: a new 4.5-
mm-wide implant (test) and the 3.75-mm-wide previous
generation implant (control), both loaded with the bone
conduction device at 3 weeks. The test implant exhibited
significantly higher ISQ values than the control implant.
All other clinical outcomes were comparable between the
implants. Quality of life generally improved in the aided
condition compared to before implantation.
The strengths of the current study include the absence of
cases lost to follow-up and the conscientiously followed
prospective study protocol. The tightly spaced follow-up
visits allow for a detailed analysis of the development of
the implants’ stability. Therefore, the study design yielded
useful information on short-term clinical results for both
implants. The study’s strength lies also in the fact that only
a single parameter, the implant width/design, was varied. A
limitation of the current study was the non-blinded follow-
up for the investigators and patients.
Both implants exhibited positive trends in ISQ mea-
surements that generally increased from baseline until the
final follow-up at 6 months. These positive trends are an
indication of a progression in implant stability over time.
RFA application in bone-anchored hearing implants has
gained increasing interest in recent years. However, to date,
reporting standards vary widely. Therefore, comparisons
between different studies should be made very carefully.
Foghsgaard and Caye-Thomasen [8] also studied the test
implant and found an increasing trend in ISQ in the first
year after surgery; however, they noted a slight decrease at
the second follow-up visit (mean 7.3 weeks), when loading
was applied. In our results, the ISQ was never lower than at
surgery. It is worth noting not only that the test implant
gave higher ISQ values on average, as expected, but also
Table 2 Subjective benefit as measured by the GBI
Variables (SD) Test (n = 38) Control (n = 21) p value
Total score 34.2 (19.2) 34.5 (16.6) 0.8384
General subscale 47.8 (25.1) 48.8 (22.5) 0.9223
Social subscale 11.3 (20.8) 9.52 (17.9) 0.9472
Physical subscale 3.1 (15.4) 3.2 (21.5) 0.1571
Fig. 4 Subjective benefit as measured by the APHAB and GHSI
questionnaires, completed before surgery and after 6 months of
follow-up. The subscales of the APHAB are represented by the
abbreviations on the x axis: EC ease of communication, BN
background noise, RV reverberation, and AV aversiveness of sounds
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that the increase in ISQ over time was significantly higher
for the test implant than the control implant. Although the
present investigation was limited to adult patients with
normal bone quality, it might be anticipated that the posi-
tive outcomes of the test implant could improve treatment
outcomes in pediatric patients and patients with compro-
mised bone quality. In comparable prospective studies on
another wide implant type, increasing ISQ trends were
reported in the first 6 months as well [10, 11], with a dip in
the ISQ at the first follow-up visit after surgery (10 days).
A 3-year follow-up on those implants revealed somewhat
decreasing trends in ISQs beginning 2 years after implan-
tation [9]. It will be interesting to extend the follow-up
period of the current study to observe ISQ trends in
comparison.
At this moment, the clinical implications of absolute
ISQ values are not yet understood, so only trends should be
evaluated. Additionally, in dental implantology, there is
still a lack of studies documenting clear clinical benefits
from therapeutic decisions based on RFA [13]. The large
number of different implant designs in dental implantology
might also influence this.
The implant survival rate was 100 % for both implants.
The same percentage was reported for the current test
implant in another 1-year follow-up prospective case series
[8]. An implant survival rate of 96.8 % was reported on the
current control implant in a retrospective case series with a
mean follow-up period of 16.9 months (range
12.1–25.2 months) [17]. These survival rates are slightly
higher than those reported in 2 other prospective studies on
a different wide implant type [10, 11]. Although all of these
are short-term results, the first year after surgery has been
reported to be critical, as more than half of implant losses
occur in the first year after surgery [4]. The current study
will be extended to compare the results to long-term sur-
vival figures from retrospective analyses. Varying survival
rates of 81.5–98.4 % with maximum follow-up periods of
up to 32.5 years have been reported on previous generation
implants (3.75-mm diameter flange fixtures with a design
comparable to that of the current control implant) [4–6].
Soft tissue tolerability was comparably good in both the
test and control implants, with incidental adverse Holgers
grade 2 and 3 skin reactions. This was expected because
the abutment, which is believed to mainly influence the
skin outcomes, was the same for both the test and control
groups. The current adverse soft tissue events are compa-
rable or even slightly better than rates reported from this
center in the studies of another type of wide implant [10,
11], also installed with skin thinning techniques. A re-
markable fact is that 2 out of 5 patients who presented with
adverse skin reactions suffered from skin diseases, which is
a higher incidence than in the study population as a whole.
This is in agreement with earlier observations [18, 19] and
the more recent identification of skin diseases as risk fac-
tors for skin reactions around bone-anchored hearing im-
plants in a large retrospective cohort study [den Besten
et al. (2014), manuscript accepted for publication in Otol-
ogy & Neurotology].
As both implants were loaded at 3 weeks after implan-
tation, the current study established that early loading did
not affect the positive ISQ trend and short-term clinical
outcomes. This is confirmed by another study of the current
control implant that reported on a loading time as early as
2 weeks after implantation [20]. Early loading of 2, 3, and
4 weeks has also been studied on another type of wide
implant with promising short-term results [10, 21, 22].
Hearing-related quality of life improved due to the
system as a whole, as patients reported improvements on
both the APHAB and GHSI questionnaires from pre-im-
plantation to 6 months later. The aided APHAB outcome is
comparable to a similar-sized population with single-sided
deafness fitted with bone conduction devices [23] and
better than a larger population of elderly patients fitted with
bone conduction devices for mixed indications [24]. The
APHAB outcome can be strongly influenced by the sound
processor used, with modern sound processors producing
significantly better aided APHAB scores than older tech-
nologies [25]. To our knowledge, the GHSI has not been
used to evaluate quality of life improvements with percu-
taneous bone conduction devices. GBI scores were also
positive and comparable between groups. The current GBI
outcome compares positively to other studies that used the
GBI to establish benefit from bone conduction systems (see
Table 3 in Faber et al. [10]). It should be emphasized that
indications and patient characteristics influence quality of
life, so comparisons with these other studies should be
made carefully. Intra-study comparisons of aided vs
unaided conditions are, therefore, more important than in-
ter-study comparisons.
Conclusion
After 6 months of follow-up, outcomes of a new 4.5-mm
diameter percutaneous implant for bone conduction devices
compared to the previous generation 3.75-mm di-
ameter implant exhibited higher ISQ values and similarly
promising clinical characteristics. No implants were lost,
and soft tissue tolerability was good. Loading both implants
at 3 weeks appeared to be safe and hearing-related quality
of life improved. These positive short-term results indicate
that the new implant and its corresponding hearing devices
loaded at 3 weeks is a safe option for hearing rehabilitation.
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